Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.

Simsek, Eda; Eskazan, AHMET; Cengiz, Mahir; Ar, MUHLİS; Ekizoglu, SEDA; Salihoglu, AYŞE; Gulturk, Emine; Elverdi, TUĞRUL; Aydin, Seniz; Demiroz, AHU; Buyru, Ayse; Baslar, ZAFER; Ozbek, Ugur; Ferhanoglu, Burhan; Aydin, Yıldız; Tuzuner, Nukhet; Soysal, Teoman

doi:10.1136/jclinpath-2015-203320

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.

Simsek E. T., Eskazan A. E., Cengiz M., Ar M. C., Ekizoglu S., Salihoglu A., ...Daha Fazla

Journal of clinical pathology, cilt.69, sa.9, ss.810-6, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 69 Sayı: 9
Basım Tarihi: 2016
Doi Numarası: 10.1136/jclinpath-2015-203320
Dergi Adı: Journal of clinical pathology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.810-6
Anahtar Kelimeler: CML, MYELOFIBROS, HEMATOPATHOLOGY, CHRONIC MYELOGENOUS LEUKEMIA, KINASE INHIBITOR STI571, CHRONIC-PHASE, RELEVANCE, THERAPY, RECOMMENDATIONS, DIAGNOSIS
İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.